Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Graham Radford-Smith

Showing results (31-40 of 73) with videos related to

Pageof 8
Sort By:
Free Radical Biology & Medicine|November 27, 2013
Selenoprotein S is a marker but not a regulator of endoplasmic reticulum stress in intestinal epithelial cellsBodo Speckmann, Kirsten Gerloff, Lisa Simms, et al.
Alimentary Pharmacology & Therapeutics|November 27, 2019
A validated risk stratification tool for detecting high-risk small bowel Crohn's diseaseEddie X Shen, Anton Lord, James D Doecke, et al.
Digestive Diseases and Sciences|November 28, 2018
Detectable Laboratory Abnormality Is Present up to 12 Months Prior to Diagnosis in Patients with Crohn's DiseaseJames R Irwin, Emma Ferguson, Lisa A Simms, et al.
Journal of Gastroenterology and Hepatology|June 15, 2007
Relationship between disease severity, quality of life and health-care resource use in a cross-section of Australian patients with Crohn's diseasePeter R Gibson, Adèle R Weston, Amelia Shann, et al.
Clinical & Translational Immunology|August 2, 2019
Crohn's disease is facilitated by a disturbance of programmed death-1 ligand 2 on blood dendritic cellsRebecca Faleiro, Ji Liu, Deshapriya Karunarathne, et al.
World Journal of Gastroenterology|November 30, 2016
Dysregulation of innate immunity in ulcerative colitis patients who fail anti-tumor necrosis factor therapyAngela C Baird, Dominic Mallon, Graham Radford-Smith, et al.
Rheumatology and Therapy|August 27, 2021
Systematic Review and Meta-Analysis of Inflammatory Bowel Disease Adverse Events with Anti-Interleukin 17A Agents and Tumor Necrosis Factor Inhibitors in Rheumatic Disease and Skin PsoriasisSteven L Truong, Jasmine Chin, David F L Liew, et al.
Human Brain Mapping|November 23, 2021
Microbiota links to neural dynamics supporting threat processingCaitlin V Hall, Ben J Harrison, Kartik K Iyer, et al.
Gastroenterology|June 16, 2007
Two-year combination antibiotic therapy with clarithromycin, rifabutin, and clofazimine for Crohn's diseaseWarwick Selby, Paul Pavli, Brendan Crotty, et al.
Inflammatory Bowel Diseases|May 4, 2007
Response and remission are associated with improved quality of life, employment and disability status, hours worked, and productivity of patients with ulcerative colitisWalter Reinisch, William J Sandborn, Mohan Bala, et al.
Pageof 8

Showing results (31-40 of 73) with videos related to

Sort By:
Pageof 8
Free Radical Biology & Medicine|November 27, 2013
Selenoprotein S is a marker but not a regulator of endoplasmic reticulum stress in intestinal epithelial cellsBodo Speckmann, Kirsten Gerloff, Lisa Simms, et al.
Alimentary Pharmacology & Therapeutics|November 27, 2019
A validated risk stratification tool for detecting high-risk small bowel Crohn's diseaseEddie X Shen, Anton Lord, James D Doecke, et al.
Digestive Diseases and Sciences|November 28, 2018
Detectable Laboratory Abnormality Is Present up to 12 Months Prior to Diagnosis in Patients with Crohn's DiseaseJames R Irwin, Emma Ferguson, Lisa A Simms, et al.
Journal of Gastroenterology and Hepatology|June 15, 2007
Relationship between disease severity, quality of life and health-care resource use in a cross-section of Australian patients with Crohn's diseasePeter R Gibson, Adèle R Weston, Amelia Shann, et al.
Clinical & Translational Immunology|August 2, 2019
Crohn's disease is facilitated by a disturbance of programmed death-1 ligand 2 on blood dendritic cellsRebecca Faleiro, Ji Liu, Deshapriya Karunarathne, et al.
World Journal of Gastroenterology|November 30, 2016
Dysregulation of innate immunity in ulcerative colitis patients who fail anti-tumor necrosis factor therapyAngela C Baird, Dominic Mallon, Graham Radford-Smith, et al.
Rheumatology and Therapy|August 27, 2021
Systematic Review and Meta-Analysis of Inflammatory Bowel Disease Adverse Events with Anti-Interleukin 17A Agents and Tumor Necrosis Factor Inhibitors in Rheumatic Disease and Skin PsoriasisSteven L Truong, Jasmine Chin, David F L Liew, et al.
Human Brain Mapping|November 23, 2021
Microbiota links to neural dynamics supporting threat processingCaitlin V Hall, Ben J Harrison, Kartik K Iyer, et al.
Gastroenterology|June 16, 2007
Two-year combination antibiotic therapy with clarithromycin, rifabutin, and clofazimine for Crohn's diseaseWarwick Selby, Paul Pavli, Brendan Crotty, et al.
Inflammatory Bowel Diseases|May 4, 2007
Response and remission are associated with improved quality of life, employment and disability status, hours worked, and productivity of patients with ulcerative colitisWalter Reinisch, William J Sandborn, Mohan Bala, et al.
Pageof 8